ECM
STOK icon

ExodusPoint Capital Management’s Stoke Therapeutics STOK Stock Holding History

ExodusPoint Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,702
Closed -$202K – 2108
2022
Q3 		$202K Buy
+15,702
New +$250K ﹤0.01% 1637
2021
Q1 		– Sell
-4,944
Closed -$306K – 2583
2020
Q4 		$306K Buy
+4,944
New +$227K ﹤0.01% 1532

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

ExodusPoint Capital Management's STOK Position: Q4 2022 in Review

ExodusPoint Capital Management sold out of Stoke Therapeutics (STOK) in Q4 2022, closing a stake of 15,702 shares — an estimated $202K sold.

ExodusPoint Capital Management first reported a position in STOK in Q4 2020 and held it in 2 quarters. The position peaked at $306K in Q4 2020. 107 funds tracked by Wall St. Rank hold STOK as of Q4 2022.

  • ExodusPoint Capital Management reported no remaining Stoke Therapeutics position as of Q4 2022 after selling out during the quarter.
  • ExodusPoint Capital Management sold 15,702 Stoke Therapeutics shares in Q4 2022, an estimated $202K.
  • ExodusPoint Capital Management first reported a position in Stoke Therapeutics in Q4 2020 and held it in 2 quarters.
  • ExodusPoint Capital Management's Stoke Therapeutics position peaked at $306K in Q4 2020.
  • 107 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2022.

Based on ExodusPoint Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.